Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) EBT (2017 - 2025)

Cue Biopharma (CUE) has disclosed EBT for 9 consecutive years, with $23.2 million as the latest value for Q4 2025.

  • Quarterly EBT fell 1.73% to $23.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Dec 2025, up 31.6% year-over-year, with the annual reading at -$4.7 million for FY2025, 32.45% up from the prior year.
  • EBT hit $23.2 million in Q4 2025 for Cue Biopharma, up from -$7.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $23.6 million in Q4 2024 to a low of -$14.3 million in Q1 2022.
  • Historically, EBT has averaged -$7.9 million across 5 years, with a median of -$11.5 million in 2022.
  • Biggest five-year swings in EBT: tumbled 80.42% in 2022 and later surged 282.69% in 2024.
  • Year by year, EBT stood at -$7.9 million in 2021, then crashed by 80.42% to -$14.2 million in 2022, then rose by 9.18% to -$12.9 million in 2023, then soared by 282.69% to $23.6 million in 2024, then decreased by 1.73% to $23.2 million in 2025.
  • Business Quant data shows EBT for CUE at $23.2 million in Q4 2025, -$7.4 million in Q3 2025, and -$8.4 million in Q2 2025.